Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $22 price target.

byBenzinga Newsdesk

March 17, 2023

1 minute read

HC Wainwright & Co. analyst Robert Burns reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $22 price target.

Robinhood’s Investor Alphabet Sells Off Final Stake In Trading App

By Benzinga Newsdesk

November 13, 11:19 AM

Alphabet Inc, Google's parent company, fully divests its stake in online trading platform Robinhood Markets Inc.

GOOG

Lineage Cell Therapeutics Announces $14M Million Registered Direct Offering

By Benzinga Newsdesk

February 6, 10:17 AM

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive

LCTX

Freedom Is Electric: Dodge Ram EV Trademarks Could Point To Features Of Highly Anticipated Pickup Truck

By Chris Katje

December 29, 1:32 PM

One of the bestselling pickup trucks could be nearing its public unveiling and bring more competition to an already heated field.

Analyst Ratings

Analyst Ratings For Augmedix

By Benzinga Insights

April 9, 4:00 PM

4 analysts have expressed a variety of opinions on Augmedix (NASDAQ:AUGX) over the past quarter, offering a diverse…

AUGX

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target

Related Posts

Robinhood’s Investor Alphabet Sells Off Final Stake In Trading App

Lineage Cell Therapeutics Announces $14M Million Registered Direct Offering

Freedom Is Electric: Dodge Ram EV Trademarks Could Point To Features Of Highly Anticipated Pickup Truck

Analyst Ratings For Augmedix